BioVentrix Achieves 2019 NUB Reimbursement Status 1 in Germany for Revivent TC™ TransCatheter Ventricular Enhancement System

SAN RAMON, Calif., Feb. 28, 2019 /PRNewswire/ -- BioVentrix, Inc., a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced a significant reimbursement achievement. InEk, the German Institute for Hospital Remuneration, has reconfirmed the ...

from PR Newswire: https://ift.tt/2tDKBL8